
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. is demonstrating a positive outlook due to its focused development of innovative therapies that address significant unmet medical needs, particularly in oncology and metabolic diseases. The company has recorded over 65% of participants in their clinical trials reporting reductions in pain and pruritus, indicating considerable progress in symptom improvement for patients. Additionally, Hoth's second quarter 2025 results highlighted disciplined expense management while advancing its lead asset, HT-001, into a broader development phase, suggesting a strong commitment to growth and operational efficiency.
Bears say
Hoth Therapeutics Inc reported no revenues for the second quarter of 2025, consistent with expectations, while total operating expenses decreased to $2.2 million from $3.4 million in the previous quarter. The company incurred a net loss of $2.2 million, translating to a loss of $(0.17) per share. This financial performance highlights ongoing operational challenges and raises concerns about the company's ability to generate revenue in the near term, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares